Cargando...
Neurocognition in Maraviroc- Compared to Tenofovir: A Double Blind Randomized Placebo Controlled Trial ACTG A5303
OBJECTIVE: To determine whether maraviroc (MVC) has unique neurocognitive benefits in the context of initial antiretroviral therapy (ART). DESIGN: Randomized, double-blind, placebo-controlled, 48-week trial SETTING: Participants were enrolled in US domestic ACTG clinical trial sites. PARTICIPANTS: 2...
Gardado en:
| Publicado en: | AIDS |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5014739/ https://ncbi.nlm.nih.gov/pubmed/27333088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000001189 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|